{"nctId":"NCT02218008","briefTitle":"A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - FORWARD-5 Study","startDateStruct":{"date":"2014-07"},"conditions":["Major Depressive Disorder"],"count":407,"armGroups":[{"label":"High Dose","type":"EXPERIMENTAL","interventionNames":["Drug: ALKS 5461"]},{"label":"Low Dose","type":"EXPERIMENTAL","interventionNames":["Drug: ALKS 5461"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"ALKS 5461","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Have a BMI of 18.0 to 40.0 kg/m2, inclusive\n* Agree to use an acceptable method of contraception for the duration of the study\n* Have an MDD primary diagnosis\n* Have no more than 2 inadequate responses to antidepressant therapy (ADT) in the current Major Depressive Episode (MDE)\n* Additional criteria may apply\n\nExclusion Criteria:\n\n* Have a current primary Axis-I disorder other than MDD\n* Have used opioid agonists (eg, codeine, oxycodone, tramadol, morphine) or opioid antagonists (eg, naloxone, naltrexone) within 14 days\n* Have received electroconvulsive therapy treatment within the last 2 years or received more than one course of electroconvulsive treatment during their lifetime\n* Have attempted suicide within the past 2 years\n* Have a positive test for drugs of abuse\n* Are pregnant, planning to become pregnant, or breastfeeding\n* Have a history of intolerance, allergy, or hypersensitivity to buprenorphine or opioid antagonists (eg, naltrexone, naloxone)\n* Have had a significant blood loss or blood donation within 60 days\n* Additional criteria may apply","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"70 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change in Montgomery Asberg Depression Rating Scale (MADRS)-6 Score Using Average of Changes From Baseline to Week 3 Through the End of Treatment Period (Week 5 for Stage 1, Week 6 for Stage 2)","description":"The MADRS-6 scale is a clinician-administered questionnaire used to measure the severity of MDD symptoms. The MADRS-6 scale is a subset of the MADRS-10 scale, comprised of the following individual questionnaire items: Apparent Sadness, Reported Sadness, Inner Tension, Lassitude, Inability to Feel, and Pessimistic Thoughts. Scores range from 0 (no apparent symptoms) to 36 (most severe symptoms).","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.6","spread":"0.34"},{"groupId":"OG001","value":"-6.0","spread":"0.74"},{"groupId":"OG002","value":"-6.8","spread":"0.75"},{"groupId":"OG003","value":"-1.5","spread":"0.65"},{"groupId":"OG004","value":"-2.2","spread":"0.67"},{"groupId":"OG005","value":"-3.2","spread":"0.67"}]}]}]},{"type":"PRIMARY","title":"Change in MADRS-10 Score Using Average of Changes From Baseline to Week 3 Through the End of Treatment Period (Week 5 for Stage 1, Week 6 for Stage 2)","description":"The MADRS-10 scale is a clinician-administered questionnaire comprised of 10 items used to measure the severity of MDD symptoms. Scores range from 0 (no apparent symptoms) to 60 (most severe symptoms). Individual questionnaire items include: Apparent Sadness, Reported Sadness, Inner Tension, Reduced Sleep, Reduced Appetite, Concentration Difficulties, Lassitude, Inability to Feel, Pessimistic Thoughts, and Suicidal Thoughts.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-8.1","spread":"0.48"},{"groupId":"OG001","value":"-8.8","spread":"1.05"},{"groupId":"OG002","value":"-10.3","spread":"1.06"},{"groupId":"OG003","value":"-2.1","spread":"0.88"},{"groupId":"OG004","value":"-3.2","spread":"0.91"},{"groupId":"OG005","value":"-3.7","spread":"0.90"}]}]}]},{"type":"PRIMARY","title":"Change From Baseline to End of Treatment in the MADRS-10","description":"The MADRS-10 scale is a clinician-administered questionnaire comprised of 10 items used to measure the severity of MDD symptoms. Scores range from 0 (no apparent symptoms) to 60 (most severe symptoms). Individual questionnaire items include: Apparent Sadness, Reported Sadness, Inner Tension, Reduced Sleep, Reduced Appetite, Concentration Difficulties, Lassitude, Inability to Feel, Pessimistic Thoughts, and Suicidal Thoughts.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-9.2","spread":"0.55"},{"groupId":"OG001","value":"-10.3","spread":"1.19"},{"groupId":"OG002","value":"-10.8","spread":"1.22"},{"groupId":"OG003","value":"-1.9","spread":"0.96"},{"groupId":"OG004","value":"-3.4","spread":"0.98"},{"groupId":"OG005","value":"-3.6","spread":"0.98"}]}]}]},{"type":"SECONDARY","title":"Proportion of Patients Who Exhibited Treatment Response (MADRS-10)","description":"The proportion of subjects demonstrating MADRS-10 treatment response, defined as a ≥ 50% reduction in MADRS-10 score from baseline to the end of the efficacy period (week 5). The MADRS-10 scale is a clinician-administered questionnaire comprised of 10 items used to measure the severity of MDD symptoms. Scores range from 0 (no apparent symptoms) to 60 (most severe symptoms). Individual questionnaire items include: Apparent Sadness, Reported Sadness, Inner Tension, Reduced Sleep, Reduced Appetite, Concentration Difficulties, Lassitude, Inability to Feel, Pessimistic Thoughts, and Suicidal Thoughts.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"61","spread":null},{"groupId":"OG001","value":"17","spread":null},{"groupId":"OG002","value":"16","spread":null},{"groupId":"OG003","value":"7","spread":null},{"groupId":"OG004","value":"7","spread":null},{"groupId":"OG005","value":"6","spread":null}]},{"measurements":[{"groupId":"OG000","value":"212","spread":null},{"groupId":"OG001","value":"45","spread":null},{"groupId":"OG002","value":"47","spread":null},{"groupId":"OG003","value":"53","spread":null},{"groupId":"OG004","value":"55","spread":null},{"groupId":"OG005","value":"57","spread":null}]}]}]},{"type":"SECONDARY","title":"Remission Rate","description":"The proportion of subjects achieving remission, defined as a MADRS-10 score of ≤10 at the end of the efficacy period.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"31","spread":null},{"groupId":"OG001","value":"8","spread":null},{"groupId":"OG002","value":"8","spread":null},{"groupId":"OG003","value":"4","spread":null},{"groupId":"OG004","value":"6","spread":null},{"groupId":"OG005","value":"5","spread":null}]},{"measurements":[{"groupId":"OG000","value":"242","spread":null},{"groupId":"OG001","value":"54","spread":null},{"groupId":"OG002","value":"55","spread":null},{"groupId":"OG003","value":"56","spread":null},{"groupId":"OG004","value":"56","spread":null},{"groupId":"OG005","value":"58","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Adverse Events (AEs)","description":null,"paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"151","spread":null},{"groupId":"OG001","value":"37","spread":null},{"groupId":"OG002","value":"42","spread":null},{"groupId":"OG003","value":"25","spread":null},{"groupId":"OG004","value":"29","spread":null},{"groupId":"OG005","value":"25","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":280},"commonTop":["Nausea","Headache","Dizziness","Constipation","Nasopharyngitis"]}}}